The role of gender in the long-term prognosis of patients with myocardial infarction submitted to fibrinolytic treatment

Ann Epidemiol. 2004 Jan;14(1):17-23. doi: 10.1016/s1047-2797(03)00076-0.

Abstract

Purpose: To determine the role of gender in short- and long-term survival after a thrombolytic-treated myocardial infarction.

Methods: A total of 686 consecutive patients with ST-elevation acute myocardial infarction, admitted to a single center and treated with intravenous streptokinase, were studied prospectively and consecutively. Assessment of clinical and in-hospital variables permitted comparison of baseline characteristics and both in-hospital and long-term survival between men and women.

Results: A significantly (odds ratio=0.48, P=0.009) lower 14-day mortality rate for males (8.5%) relative to females (16%) was noted. However, this difference became non-significant after adjustment for age (odds-ratio male/female=0.62, P=0.097) or age and other variables (odds ratio=0.71, P=0.17). At the end of the follow-up (up to 12 years), survival rates for the whole population were 59.6% and 54.4% for men and women, respectively (chi-square=1.4, P=0.24); excluding in-hospital deaths, the rates were 65.1% and 64.8%, respectively (chi-square=0.21, P=0.65).

Conclusions: In the short-term follow-up, women have a significantly higher mortality relative to men in an unadjusted analysis. This difference became non-significant after adjusting for age, or age and other variables. In the long-term follow-up, sex was not correlated with prognosis.

Publication types

  • Comparative Study

MeSH terms

  • Brazil / epidemiology
  • Cardiac Catheterization
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Follow-Up Studies
  • Hospitalization
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / diagnosis
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / mortality*
  • Myocardial Infarction / therapy
  • Prognosis
  • Prospective Studies
  • Risk Factors
  • Sex Factors
  • Streptokinase / therapeutic use*
  • Survival Analysis
  • Time
  • Treatment Outcome*

Substances

  • Fibrinolytic Agents
  • Streptokinase